Zemaira
Payments companies reported to CMS as associated with Zemaira. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Zemaira, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Zemaira
These are the largest totals companies reported as associated with Zemaira. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Friedrich Kueppers | Philadelphia, PA | Pulmonary Disease | $28,601.32 |
| Charlton Strange | Charleston, SC | Critical Care Medicine (Internal Medicine) | $23,760.55 |
| Jennifer Holter-Chakrabarty | Oklahoma City, OK | Hematology & Oncology | $11,700.00 |
| Melvin Berger | Cleveland, OH | Pediatric Allergy/Immunology | $11,550.00 |
| Amin Alousi | Houston, TX | Internal Medicine | $9,565.55 |
| Robert Sandhaus | Denver, CO | Pulmonary Disease | $4,351.47 |
| Matthew Gordon | Marlton, NJ | Pulmonary Disease | $3,285.00 |
| Maruti Kumaran | Philadelphia, PA | Diagnostic Radiology | $3,285.00 |
| Andrew Gangemi | Philadelphia, PA | Internal Medicine | $3,285.00 |
| Eric Sandwith | Fort Walton Beach, FL | Thoracic Surgery (Cardiothoracic Vascular Surgery) | $3,285.00 |
Prescribed Zemaira?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.